COMPANY

Forte Biosciences

HQ: Dallas, TX source · fortebiorx.com ↗ · Southwest

Forte Biosciences' website states that it is now part of argenx. Forte is a clinical-stage company whose lead product candidate FB102 is being developed for autoimmune and autoimmune-related conditions, including celiac disease (Phase 2), vitiligo and alopecia areata. A Phase 1 study of FB-102 in healthy volunteers is registered. Source

Sources: Company website · ISRCTN registry (checked Oct 12, 2026)

Keywords: autoimmune celiac disease vitiligo alopecia areata FB102 argenx Dallas TX Atopic Dermatitis Alopecia Areata Vitiligo Celiac Disease FB102 FB-401

Clinical Phase 2

Location: Dallas, TX · source · Oct 14, 2026

Profile checked Oct 10, 2026

6Trials (company is sponsor)

Timeline

Jun 23, 2026 Trial start Phase 1: A Study Testing the Safety and Effects of FB102 in Healthy Volunteers source ↗
Oct 23, 2025 Trial start Phase 1: A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata. source ↗
Aug 4, 2025 Trial start 2: Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease source ↗
Mar 25, 2025 Trial start Phase 1: A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo source ↗
Jun 2, 2021 Trial start Phase 2: Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 Study source ↗
Oct 13, 2020 Trial start Phase 2: Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis source ↗

Upcoming milestones

Dec 31, 2026 (ESTIMATED) · Phase 1 · A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo · NCT06905873
2027-02 (ESTIMATED) · Phase 1 · A Study Testing the Safety and Effects of FB102 in Healthy Volunteers · NCT07623057
Feb 28, 2027 (ESTIMATED) · 2 · Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease · NCT06982963
Mar 10, 2027 (ESTIMATED) · Phase 1 · A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata. · NCT07205159

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 6

Record	Title	Phase	Status	Start	Primary completion
NCT07623057	A Study Testing the Safety and Effects of FB102 in Healthy Volunteers	Phase 1	Recruiting	Jun 23, 2026	2027-02 (estimated)
NCT07205159	A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.	Phase 1	Recruiting	Oct 23, 2025	Mar 10, 2027 (estimated)
NCT06905873	A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo	Phase 1	Recruiting	Mar 25, 2025	Dec 31, 2026 (estimated)
NCT06982963	Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease	2	Recruiting	Aug 4, 2025	Feb 28, 2027 (estimated)
NCT04936113	Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 Study	Phase 2	Terminated	Jun 2, 2021	Sep 30, 2021 (actual)
NCT04504279	Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis	Phase 2	Completed	Oct 13, 2020	Jul 14, 2021 (actual)